title: Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).
abstract: This part of our study presents results of laboratory evaluations in patients with BPH during treatment with prazosin and doxazosin. After 72 weeks serum PSA and PAP fell by 40.2% and 82%, respectively. Blood urea nitrogen concentration decreased by 28.5% and serum creatinine by 20.8%. The results confirm long-term favourable effects of the therapy of patients with BPH.
authors.affiliation: Department of Urology, Ministry of Internal Affairs Central Clinical Hospital, Warsaw, Poland.
authors.forename: S
authors.initials: S
authors.lastname: Dutkiewicz
authors.forename: A
authors.initials: A
authors.lastname: Witeska
authors.forename: K
authors.initials: K
authors.lastname: Stepień
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D017292:Doxazosin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011224:Prazosin / Q000627:therapeutic use; D011467:Prostate; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000317:Adrenergic alpha-Antagonists; D003404:Creatinine; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen; D017292:Doxazosin; D011224:Prazosin